Neal Shore, MD, FACS, discusses the safety profiles reported across the nadofaragene firadenovec, SunRISe-1, and NURE-COMBO trials, highlighting any unexpected toxicities observed with these novel therapies for non-muscle-invasive and muscle-invasive bladder cancer. Additionally, he reviews key limitations of the study designs or patient populations that may impact the interpretation and generalizability of the results from these trials.
NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC
ajmc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ajmc.com Daily Mail and Mail on Sunday newspapers.
Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC
ajmc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ajmc.com Daily Mail and Mail on Sunday newspapers.
Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC
ajmc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ajmc.com Daily Mail and Mail on Sunday newspapers.